Therapy: The second time as farce: rosiglitazone and the regulators

Nat Rev Endocrinol. 2011 Jan;7(1):5-6. doi: 10.1038/nrendo.2010.209. Epub 2010 Nov 23.


Rosiglitazone is the second of the marketed thiazolidinediones to fall from grace, and its demise bears an uncanny resemblance to the earlier downfall of troglitazone. Both narratives demonstrate the inadequacy of a regulatory system that is mandated to place a higher value on commercial secrecy than on patient safety.

Publication types

  • News

MeSH terms

  • Chromans / adverse effects
  • Chromans / therapeutic use
  • Diabetes Mellitus / drug therapy
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Rosiglitazone
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / therapeutic use*
  • Troglitazone


  • Chromans
  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone
  • Troglitazone